Sinovac Biotech

Sinovac Amends Shareholder Rights Plan

Retrieved on: 
Wednesday, February 21, 2024
Health, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Sinovac Biotech

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan.

Key Points: 
  • Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan.
  • The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025.

Global Influenza Vaccine Market Research Report 2023-2028: Analysis by Valency, Vaccine Type, Technology, Age Group, RoA, Distribution Channel, Region Size and Trends with Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 10, 2023
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Market, Government, COVID-19, Death, Public, Vaccine, Intelligence, US, Distribution, Long COVID, Route of administration, Prevalence, COVID, Risk, Hospital, Mortality, Valence, Disease, WHO, World Health Organization, Patient, Sinovac Biotech, Good, Vaccination, Growth, Food and Drug Administration, Pregnancy, Research, Pharmacy

The global influenza vaccine market in 2022 stood at US$7.98 billion, and is likely to reach US$12.32 billion by 2028.

Key Points: 
  • The global influenza vaccine market in 2022 stood at US$7.98 billion, and is likely to reach US$12.32 billion by 2028.
  • The global influenza vaccine market value is projected to grow at a CAGR of 7.50%, during the forecast period of 2023-2028.
  • Thus, representing a need and large market opportunity for the influenza vaccine market.
  • Global Influenza Vaccine Market by Distribution Channel (Hospitals and Pharmacies, Government and Institutions and Others)
    Global Influenza Vaccine Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

China Review Studio and Chinese Red Cross Foundation Release "Generation Vax" Documentary for Broadcast Internationally

Retrieved on: 
Monday, October 2, 2023
Volunteering, Instituto Butantan, University, School of Public Health, COVID-19, Infection, ATV, Chinese Academy of Medical Sciences COVID-19 vaccine, Research, TVT, SPB, Chinese Academy of Engineering, Science, BFC, University of Hong Kong, Public health, Sinopharm (company), School, Mass vaccination, RED, III, United Arab Emirates, Safety, Sinopharm Group, Vaccine, Sinovac Biotech, SEA

BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese Red Cross Foundation recently released a documentary on YouTube named Generation Vax. Directed by internationally renowned director Mitchell Farkas, the film focuses on the theme of China's Covid-19 vaccine by deeply diving into the safety, effectiveness, and publicity of China's vaccines.

Key Points: 
  • BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese Red Cross Foundation recently released a documentary on YouTube named Generation Vax.
  • Directed by internationally renowned director Mitchell Farkas, the film focuses on the theme of China's Covid-19 vaccine by deeply diving into the safety, effectiveness, and publicity of China's vaccines.
  • The film also reveals the story of how clinical phase III of China's vaccine has been conducted in Brazil.
  • The second half of the film documents China's calls for the world to work together to face down public safety incidents together.

SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection

Retrieved on: 
Monday, September 11, 2023
COVID-19, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Vaccine, Contraindication, Vaccination, University of the Chinese Academy of Sciences, Half-life, SARS-CoV-2, Infection, Clinical trial, SARS, Chinese Academy of Medical Sciences COVID-19 vaccine, Sinovac Biotech, Patient, Blood, Ageing, Immunodeficiency, Safety, Pharmaceutical industry

Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection (“SA55 Injection”) in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.

Key Points: 
  • Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection (“SA55 Injection”) in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.
  • SINOVAC’s SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023.
  • The phase I clinical trial has confirmed its preliminary safety profile in 40 healthy adults aged 18 to 65 in China.
  • China’s National Medical Products Administration has approved SINOVAC’s SA55 Nasal Spray for clinical trial in the prevention of COVID-19 infections, in April 2023.

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

Retrieved on: 
Tuesday, September 5, 2023
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Agreement, Liquidity, Shareholder, NOT, Independent Monitoring Authority for the Citizens' Rights Agreements, Tender offer, Financial assistance (share purchase), Expiration date, Rights, Securities and Exchange Commission (Nigeria), Sale, Schedule, Tender, Expiration, Investment, Alternative, Cryptocurrency, Management, Sinovac Biotech, Purchasing, Share (finance)

Accordingly, the Board of Directors recommends that the Shareholders reject the Tender Offer and not tender their Shares for purchase pursuant to the Offer to Purchase by Alternative Liquidity.

Key Points: 
  • Accordingly, the Board of Directors recommends that the Shareholders reject the Tender Offer and not tender their Shares for purchase pursuant to the Offer to Purchase by Alternative Liquidity.
  • The Tender Offer was reviewed and considered by the Board of Directors, none of whom are affiliated with Alternative Liquidity.
  • The Board of Directors took into account various factors in evaluating the Tender Offer and in support of its recommendation that the Shareholders reject the Tender Offer and not tender their shares in the Tender Offer, including the following.
  • The Board of Directors’ belief in this regard is supported by Alternative Liquidity’s own characterization of the Tender Offer.

Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer

Retrieved on: 
Tuesday, August 29, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Sinovac Biotech, Alternative, Cryptocurrency, Management

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company’s outstanding shares, for $0.03 per share in cash.

Key Points: 
  • Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company’s outstanding shares, for $0.03 per share in cash.
  • Sinovac’s Board of Directors intends to evaluate the terms of the tender offer to determine the course of action that it believes is in the best interest of the Company and its shareholders.
  • The Board also intends to advise shareholders of the Board’s position regarding the tender offer within ten business days of receipt of the offer.
  • In the meantime, the Company’s shareholders are strongly advised to take no action in relation to the tender offer.

Global Influenza Vaccines Research Analysis Report 2023: A Potential $10.9 Billion market by 2030 - Expanding Manufacturing Capabilities and Focus on Launching New Vaccines will Propel Expansion

Retrieved on: 
Tuesday, August 29, 2023
Vaccine, GSK plc, Vaccination, Influenza, Sinovac Biotech, Pfizer, AstraZeneca, CIC, Centers for Disease Control and Prevention, Government, CDC, Trial of the century, Death, Incidence, Pandemic, Investment, Risk, Sanofi, Growth, Ageing, WHO, Immunization, Messenger, World Health Organization, Pharmaceutical industry, EU, CSL Limited

The increasing R&D investments by leading market players, such as Sanofi, CSL Limited, and GlaxoSmithKline, for expanding manufacturing capabilities and focus on launching new vaccines will propel the market for influenza vaccines over the forecast period.

Key Points: 
  • The increasing R&D investments by leading market players, such as Sanofi, CSL Limited, and GlaxoSmithKline, for expanding manufacturing capabilities and focus on launching new vaccines will propel the market for influenza vaccines over the forecast period.
  • Geographically, North America is the largest market for influenza vaccines capturing over 50% market share in 2022.
  • AstraZeneca influenza vaccines sales declined by 31% in 2022, owing to late start to the influenza season in Europe.
  • In 2021, Seqirus influenza vaccines sales increased by 37% over the prior year, driven by strong growth in seasonal influenza vaccines.

Sinovac Announces Change of Legal Representative of Sinovac Beijing

Retrieved on: 
Monday, August 28, 2023
Science, Legal, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Professional Services, Verdict, Administration, Civil Mediation Council, Assistance, Consent, Fine chemical, Automotive industry, Sinovac Biotech

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the Company’s subsidiary, Sinovac Biotech Co., Ltd. (“Sinovac Beijing”), has changed its legal representative to Mr. Weidong Yin, the Company’s Chairman, President and Chief Executive Officer.

Key Points: 
  • Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the Company’s subsidiary, Sinovac Biotech Co., Ltd. (“Sinovac Beijing”), has changed its legal representative to Mr. Weidong Yin, the Company’s Chairman, President and Chief Executive Officer.
  • The Administration for Market Regulation Bureau of Beijing Haidian District notified Sinovac Beijing that the minority shareholder and the legal representative of Sinovac Beijing have been changed in accordance with the Notice of Assistance of Court Verdict Execution, the Verdict Execution Order and the Consent Judgement on the Civil Mediation Agreement by Shandong Province Zibo City Zhangdian District People’s Court.
  • Mr. Weidong Yin has been appointed the legal representative and chairman of the board of directors of Sinovac Beijing.
  • The Administration for Market Regulation Bureau of Beijing Haidian District issued an updated business license dated August 25, 2023 to Sinovac Beijing.

SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines

Retrieved on: 
Wednesday, May 10, 2023
Health, Infectious Diseases, COVID-19, General Health, Pharmaceutical, Biotechnology, Vaccine, Infection, University, Vaccination, Immunization, Public, Parent, Sinovac Biotech, Hospital, COVID, Omicron, Multisystem inflammatory syndrome, Government, Organization, Death, Amnesia, Insomnia, Patient, Risk, Ageing, ICU, Safety, Disease, Pharmaceutical industry

Additionally, the company will collaborate with local charity groups to provide donations, giving more children in Hong Kong access to free vaccines to protect against COVID-19.

Key Points: 
  • Additionally, the company will collaborate with local charity groups to provide donations, giving more children in Hong Kong access to free vaccines to protect against COVID-19.
  • “SINOVAC’s ongoing fight against COVID-19 is based on our mission to ‘supply vaccines to eliminate human diseases,’” said Yin Weidong, Chairman, President, and CEO of SINOVAC.
  • Hospitalization and the long-term effects of COVID-19 can be serious, particularly among children, underscoring the need for accessible and affordable vaccinations and boosters.
  • SINOVAC is addressing these concerns by supplying the private market in Hong Kong with their inactivated COVID-19 vaccine, thus offering a viable solution for these patients.

Sinovac Amends Shareholder Rights Plan

Retrieved on: 
Wednesday, February 22, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Sinovac Biotech, Fine chemical

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan.

Key Points: 
  • Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan.
  • The amendment extends the expiration date of the plan from February 22, 2023 to February 22, 2024.